# A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention

Study · id `cardio:ct-nct01830543` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01830543](<https://clinicaltrials.gov/study/NCT01830543>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01830543

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2124 participants.

## Technical summary

Registry record NCT01830543. Randomized; no masking; primary purpose treatment. Start 2013-05-10 (actual); primary completion 2016-07-28 (actual). Results posted on 2017-07-31.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 2124 participants (enrolled count; ClinicalTrials.gov record NCT01830543, source copy `cardio:ctgov-nct01830543-2017-09-19`, retrieved 2026-10-26)
- Started: 2013-05-10 (actual) (ClinicalTrials.gov record NCT01830543, source copy `cardio:ctgov-nct01830543-2017-09-19`, retrieved 2026-10-26)
- Primary completion: 2016-07-28 (actual) (ClinicalTrials.gov record NCT01830543, source copy `cardio:ctgov-nct01830543-2017-09-19`, retrieved 2026-10-26)
- Completion: 2016-07-28 (actual) (ClinicalTrials.gov record NCT01830543, source copy `cardio:ctgov-nct01830543-2017-09-19`, retrieved 2026-10-26)
- Results first posted: 2017-07-31 (ClinicalTrials.gov record NCT01830543, source copy `cardio:ctgov-nct01830543-2017-09-19`, retrieved 2026-10-26)
- Countries: United States; Argentina; Australia; Belgium; Brazil; Bulgaria; Canada; Chile; Czechia; Denmark; France; Germany; Malaysia; Mexico; Netherlands; Poland; Romania; Russia; South Africa; South Korea; Sweden; Taiwan; Türkiye; Ukraine; United Kingdom (ClinicalTrials.gov record NCT01830543, source copy `cardio:ctgov-nct01830543-2017-09-19`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01830543-2017-09-19`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention
- Acronym: PIONEER AF-PCI
- Condition: Atrial Fibrillation
- Condition: Percutaneous Coronary Intervention
- Intervention (Drug): rivaroxaban 2.5 mg
- Intervention (Drug): rivaroxaban 15 mg
- Intervention (Drug): rivaroxaban 10 mg
- Intervention (Drug): aspirin (ASA)
- Intervention (Drug): vitamin K antagonist (VKA)
- Intervention (Drug): clopidogrel
- Intervention (Drug): prasugrel
- Intervention (Drug): ticagrelor
- Lead sponsor: Janssen Scientific Affairs, LLC
- Lead sponsor class: INDUSTRY
- Collaborator: Bayer
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry intervention name matches this record: Clopidogrel (`cardio:clopidogrel`)
- Registry intervention name matches this record: Prasugrel (`cardio:prasugrel`)
- Registry intervention name matches this record: Ticagrelor (`cardio:ticagrelor`)
- Registry lists this organization as the lead sponsor: Janssen Scientific Affairs, LLC (`cardio:org-janssen-scientific-affairs-llc`)
- Registry lists this organization as a collaborator: Bayer (`cardio:bayer`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI (`cardio:pubmed-27959713`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Recurrent Hospitalization Among Patients With Atrial Fibrillation Undergoing Intracoronary Stenting Treated With 2 Treatment Strategies of Rivaroxaban or a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy (`cardio:pubmed-27881555`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Effect of Procedure and Coronary Lesion Characteristics on Clinical Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention: Insights From the PIONEER AF-PCI Trial (`cardio:pubmed-29550085`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Total bleeding with rivaroxaban versus warfarin in patients with atrial fibrillation receiving antiplatelet therapy after percutaneous coronary intervention (`cardio:pubmed-29943350`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Association of International Normalized Ratio Stability and Bleeding Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention (`cardio:pubmed-30704287`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Novel Oral Anticoagulant Based Versus Vitamin K Antagonist Based Double Therapy Among Stented Patients With Atrial Fibrillation: Insights From the PIONEER AF-PCI Trial (`cardio:pubmed-31707805`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 42f17ac0bfde9ddd8359bdd53fc6ee813eadb0120bfadfa2fc95db9fde2bc4a1
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
